Translate Bio, Inc., a clinical-stage mRNA therapeutics company developing a new class of medicines to treat diseases caused by protein or gene dysfunction, has entered into a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to five undisclosed infectious disease pathogens. Sanofi Pasteur, the vaccines global business unit of Sanofi (NYSE:SNY), will make an upfront payment of $45 million to Translate Bio, and the companies will conduct joint research and development activities to advance mRNA vaccines during an initial three-year research term.
The WilmerHale team representing Translate Bio in the collaboration agreement is led by Belinda Juran and Cynthia Mazareas, and includes Ariel Soiffer and Ryan Crane.
Read Translate Bio’s press release about the collaboration.